Pinsent Masons recruits third partner in Amsterdam hiring life sciences specialist

03 Jun 2021 | 08:28 am | 1 min. read

Multinational law firm Pinsent Masons has recruited Life Sciences partner, Machteld Hiemstra in Amsterdam as it develops its Netherlands-based technology, science and industry (TSI) capabilities.

Machteld, who is the firm's third partner in The Netherlands, is a civil and regulatory litigator specialising in regulatory enforcement and compliance with an emphasis on medicines and medical devices regulatory mandates, consumer protection, GDPR, product liability and patent extension disputes.
A life sciences specialist, Machteld will advise on Pan-European and domestic matters including biologics and biotech, generics and biosimilars, medtech and digital health.
Amsterdam office head at Pinsent Masons, Wouter Seinen, said: "Building out capabilities that focus on life sciences regulatory advisory and disputes work will be a game changer for us in Amsterdam.
“Not only will Machteld's experience support the development of our global technology, science and industry sector, it will enable us to tap into opportunities prompted by the relocation of the European Medicines Association to Amsterdam as clients increasingly seek on the ground capabilities. Machteld's expertise will play an important role in adding strength and depth to our pan-European Life Sciences capabilities."
Machteld's hire follows the recruitment of TSI partner Alexander Spoor in May following the launch of Pinsent Masons' Amsterdam presence with the hire of office head Wouter Seinen in February.
Joining from Simmons & Simmons, Machteld has advised a number of high-profile businesses including GSK, Bayer, Abbott and Gilead. Her career incorporates both private practice and in-house experience working with Akzo Nobel as senior legal counsel between 2004 and 2007 where she was responsible for global pharma related product liability matters.
Commenting on her move, Machteld said: "Demand for domestic and international life sciences capabilities is increasing in Netherlands and across continental Europe. I am excited to be joining an international team with an established track record of using law as a business enabler for its clients.”

Latest press releases

Show me all press releases

Pinsent Masons wins Construction Team of the Year at the Middle East Legal Awards

Multinational law firm Pinsent Masons has won Construction Team of the Year at the Middle East Legal Awards 2021.

Pinsent Masons collaborates with LifeArc on expert paper to support drug repurposing

Multinational law firm Pinsent Masons has collaborated with medical research charity LifeArc, on a new report offering expert advice, insights and practical tips to charities, researchers and funders hoping to repurpose drugs for other – often rare and fatal – conditions.

Pinsent Masons advises UCL on £300m sustainability bond

Multinational law firm Pinsent Masons has advised University College London (UCL) on its debut issue of £300m 1.625% sustainability bonds due 2061 - the first publicly listed sustainability bonds in the higher education sector.

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons collaborates with LifeArc on expert paper to support drug repurposing

Multinational law firm Pinsent Masons has collaborated with medical research charity LifeArc, on a new report offering expert advice, insights and practical tips to charities, researchers and funders hoping to repurpose drugs for other – often rare and fatal – conditions.

Pinsent Masons advises the UK government on purchase of further 60m doses of Covid-19 vaccines

Multinational law firm Pinsent Masons has successfully advised the UK government on an agreement to purchase an additional 60m doses of the Pfizer BioNTech Covid-19 vaccine for the autumn revaccination programme.

Pinsent Masons advises Teva Pharmaceuticals on €84m sale of its consumer healthcare brand portfolio to Karo Pharma AB.

Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts